Eric Scharin is a seasoned Pharmaceutical and Biopharmaceutical Technical Operations Executive, currently serving as the CMC Technical Lead at UCB following the strategic acquisition of Zogenix in 2022. With over 20 years of experience in Chemistry, Manufacturing, and Controls (CMC) strategy and product realization, Eric...
Eric Scharin is a seasoned Pharmaceutical and Biopharmaceutical Technical Operations Executive, currently serving as the CMC Technical Lead at UCB following the strategic acquisition of Zogenix in 2022. With over 20 years of experience in Chemistry, Manufacturing, and Controls (CMC) strategy and product realization, Eric has consistently demonstrated his ability to navigate the complexities of bringing pharmaceuticals to market, particularly in dynamic, start-up environments. His extensive expertise encompasses a wide range of technical knowledge, including GMP compliance, analytical method validation, and regulatory requirements under 21 CFR Part 11, which are critical for ensuring product quality and safety.
At UCB, Eric leads key projects that focus on optimizing processes and enhancing product development timelines. His role involves overseeing change control initiatives and implementing robust quality systems that align with FDA regulations, ensuring that all operational activities meet the highest standards of compliance and efficiency. Eric’s adeptness in project management and his proficiency in Failure Mode and Effects Analysis (FMEA) empower his teams to proactively identify and mitigate risks, thereby streamlining the path from development to market.
Eric's unique blend of technical acumen and practical leadership skills enables him to foster collaboration across cross-functional teams, driving innovation while maintaining a steadfast commitment to quality. His contributions are pivotal in positioning UCB as a leader in the biopharmaceutical landscape, as he continues to leverage his knowledge and experience to deliver impactful results in the ever-evolving pharmaceutical industry.
